AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21068681 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional resistance training at 80% 1RM
Number of subjects: 38
Study 21068681 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 38
Study 18249201 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-rich meal
Number of subjects: 30
Study 18249201 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat-rich meal
Number of subjects: 30
Study 16368318 — intervention group
Group type: EXPERIMENTAL
Intervention: MECC Jostra System
Number of subjects: 400
Study 16368318 — intervention group
Group type: COMPARATOR
Intervention: Standard CPB
Number of subjects: 400
Study 12688453 — intervention group
Group type: EXPERIMENTAL
Intervention: CON‐ECC (75% concentric and 25% eccentric)
Number of subjects: 31
Study 12688453 — intervention group
Group type: EXPERIMENTAL
Intervention: ECC‐CON (75% eccentric and 25% concentric)
Number of subjects: 31
Study 12688453 — intervention group
Group type: COMPARATOR
Intervention: CON (100% concentric)
Number of subjects: 31
Study 10763950 — intervention group
Group type: EXPERIMENTAL
Intervention: IBS-QOL
Number of subjects: 0
Study 8839294 — intervention group
Group type: EXPERIMENTAL
Intervention: Tridimensional Personality Questionnaire administered to social phobia patients
Number of subjects: 47
Study 8839294 — intervention group
Group type: COMPARATOR
Intervention: Control group (N=40)
Number of subjects: 47
Study 1486247 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-peptide diet
Number of subjects: 6
Study 1486247 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed diet
Number of subjects: 6
Study 1486247 — intervention group
Group type: COMPARATOR
Intervention: Whole protein diet
Number of subjects: 6
Study 4006485 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable; trial was canceled
Number of subjects: 0
Study 30945118 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral semaglutide 20 mg once daily (steady state) with lisinopril (20 mg single dose)
Number of subjects: 84
Study 30945118 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral semaglutide 20 mg once daily (steady state) with warfarin (25 mg single dose)
Number of subjects: 84
Study 30945118 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral semaglutide 20 mg once daily (steady state) with digoxin (500 μg single dose)
Number of subjects: 84
Study 30945118 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral semaglutide 20 mg once daily (steady state) with metformin (850 mg twice daily for 4 days)
Number of subjects: 84
Study 30945118 — intervention group
Group type: COMPARATOR
Intervention: SNAC alone (300 mg single dose) with lisinopril, warfarin, digoxin, or metformin
Number of subjects: 84
Study 30206820 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimethyl Fumarate (DMF)
Number of subjects: 109
Study 30206820 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study 24177712 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic therapy (n = 24, two months, five times/week)
Number of subjects: 49
Study 24177712 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group (n = 25)
Number of subjects: 49
Study 22569030 — intervention group
Group type: EXPERIMENTAL
Intervention: Bullard laryngoscope
Number of subjects: 60
Study 22569030 — intervention group
Group type: EXPERIMENTAL
Intervention: Airtraq laryngoscope
Number of subjects: 60
Study 22569030 — intervention group
Group type: COMPARATOR
Intervention: Conventional laryngoscope
Number of subjects: 60
Study 20299736 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary calorie intake during hospitalization (25 kcal/kg IBW)
Number of subjects: 144
Study 19092257 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (1,200 mg/day)
Number of subjects: 20
Study 19092257 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 15921686 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin pretreatment (1500 mg daily for 12 days, followed by clomiphene 150 mg daily for 5 days along with metformin)
Number of subjects: 80
Study 15921686 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment (clomiphene 150 mg daily for 5 days without metformin pretreatment)
Number of subjects: 80
Study 11891671 — intervention group
Group type: EXPERIMENTAL
Intervention: Nemifitide (subcutaneous doses ranging from 18 to 320 mg)
Number of subjects: 100
Study 10825058 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous foscarnet (100 mg/[kg x 12 h])
Number of subjects: 42
Study 10825058 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 42
Study 10825058 — intervention group
Group type: EXPERIMENTAL
Intervention: Foscarnet
Number of subjects: 42
Study 8573554 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ) at a dose of 800 mg/day
Number of subjects: 10
Study 2616707 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise for 20 minutes
Number of subjects: 80
Study 2616707 — intervention group
Group type: COMPARATOR
Intervention: Waiting-period control condition
Number of subjects: 80
Study 308146 — intervention group
Group type: EXPERIMENTAL
Intervention: Naftidrofuryl
Number of subjects: 0
Study 308146 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine
Number of subjects: 0
Study 308146 — intervention group
Group type: EXPERIMENTAL
Intervention: Bencyclane
Number of subjects: 0
Study 30904674 — intervention group
Group type: EXPERIMENTAL
Intervention: aIIV3
Number of subjects: 7532
Study 30904674 — intervention group
Group type: COMPARATOR
Intervention: IIV3
Number of subjects: 7532
Study 29988707 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced physiotherapy care package (education, twice daily coached breathing exercises for a minimum of 2 days, and 30 minutes of daily supervised early rehabilitation for a minimum of five postoperative days)
Number of subjects: 288
Study 29988707 — intervention group
Group type: COMPARATOR
Intervention: Standard care physiotherapy (education, single session of coached breathing exercises, and daily early ambulation for 15 minutes)
Number of subjects: 288
Study 29988707 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced physiotherapy care package
Number of subjects: 288
Study 29988707 — intervention group
Group type: COMPARATOR
Intervention: Standard care physiotherapy
Number of subjects: 288
Study 26308708 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfacalcidol at 1 μg/day
Number of subjects: 106
Study 26308708 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 35 mg/week
Number of subjects: 106
Study 26308708 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfacalcidol plus alendronate
Number of subjects: 106
Study 26308708 — intervention group
Group type: COMPARATOR
Intervention: Commencement of glucocorticoid therapy
Number of subjects: 106
Study 25353174 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline (200mg/d) + risperidone
Number of subjects: 43
Study 25353174 — intervention group
Group type: COMPARATOR
Intervention: Placebo + risperidone
Number of subjects: 43
Study 22738922 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 771
Study 22738922 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 771
Study 18716400 — intervention group
Group type: EXPERIMENTAL
Intervention: HEPA air cleaners
Number of subjects: 36
Study 18716400 — intervention group
Group type: COMPARATOR
Intervention: Sham air cleaners
Number of subjects: 36
Study 17277715 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 338
Study 17277715 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 338
Study 15093201 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary chemotherapy
Number of subjects: 0
Study 15093201 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant treatment
Number of subjects: 0
Study 11476014 — intervention group
Group type: EXPERIMENTAL
Intervention: Silica-based, enamel-safe tartar control whitening dentifrice
Number of subjects: 291
Study 11476014 — intervention group
Group type: COMPARATOR
Intervention: Marketed baking soda dentifrice control
Number of subjects: 291
Study 11477860 — intervention group
Group type: EXPERIMENTAL
Intervention: Lentinan plus CO2 laser irradiation
Number of subjects: 36
Study 11477860 — intervention group
Group type: COMPARATOR
Intervention: Laser irradiation alone
Number of subjects: 36
Study 7829908 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleroxacin 200 mg once a day for 3 days (cholera), 7 days (Salmonella enteritis), 5 days (other infectious enteritis)
Number of subjects: 143
Study 7829908 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleroxacin 300 mg once a day for 3 days (cholera), 7 days (Salmonella enteritis), 5 days (other infectious enteritis)
Number of subjects: 143
Study 2892770 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin-28 (SS-28) 100 micrograms/h
Number of subjects: 8
Study 2892770 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin-14 (SS-14) 250 micrograms/h
Number of subjects: 8
Study 2892770 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline
Number of subjects: 8
Study 29789908 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-phasic contrast injection (25mgI/kg/s for 12 seconds in 1st phase and 3.0 ml/s for 7 seconds in 2nd phase) with two axial scans using smart-coverage technique.
Number of subjects: 60
Study 29789908 — intervention group
Group type: COMPARATOR
Intervention: Conventional protocol with contrast injection (25mgI/kg/s for 14 seconds) and helical/axial scanning.
Number of subjects: 60
Study 26618662 — intervention group
Group type: EXPERIMENTAL
Intervention: Reamed tibial nails
Number of subjects: 1319
Study 26618662 — intervention group
Group type: COMPARATOR
Intervention: Unreamed tibial nails
Number of subjects: 1319
Study 26618662 — intervention group
Group type: EXPERIMENTAL
Intervention: Reamed and unreamed tibial nails
Number of subjects: 1319
Study 25135743 — intervention group
Group type: EXPERIMENTAL
Intervention: QVA149 110/50 μg
Number of subjects: 11404
Study 25135743 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol 150 μg
Number of subjects: 11404
Study 25135743 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrronium 50 μg
Number of subjects: 11404
Study 25135743 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 18 μg
Number of subjects: 11404
Study 25135743 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11404
Study 22205617 — intervention group
Group type: EXPERIMENTAL
Intervention: roxatidine 75 mg
Number of subjects: 10
Study 22205617 — intervention group
Group type: COMPARATOR
Intervention: omeprazole 20 mg
Number of subjects: 10
Study 20061426 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH)
Number of subjects: 30
Study 20061426 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 17278943 — intervention group
Group type: EXPERIMENTAL
Intervention: Reciprocating Procedure Device (RPD)
Number of subjects: 80
Study 17278943 — intervention group
Group type: COMPARATOR
Intervention: Conventional Syringe
Number of subjects: 80
Study 16596912 — intervention group
Group type: EXPERIMENTAL
Intervention: Racemic bupivacaine 0.5% with 1 : 200,000 epinephrine
Number of subjects: 22
Study 16596912 — intervention group
Group type: EXPERIMENTAL
Intervention: 75% levobupivacaine and 25% dextrobupivacaine 0.5% with 1 : 200,000 epinephrine
Number of subjects: 22
Study 11901047 — intervention group
Group type: EXPERIMENTAL
Intervention: BG9719 alone
Number of subjects: 63
Study 11901047 — intervention group
Group type: EXPERIMENTAL
Intervention: BG9719 plus furosemide
Number of subjects: 63
Study 11901047 — intervention group
Group type: EXPERIMENTAL
Intervention: BG9719 alone (2 lower doses)
Number of subjects: 63
Study 11901047 — intervention group
Group type: COMPARATOR
Intervention: Furosemide alone
Number of subjects: 63
Study 11901047 — intervention group
Group type: EXPERIMENTAL
Intervention: BG9719 plus furosemide (2 lower doses)
Number of subjects: 63
Study 8552741 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergic skin tests administered to one forearm
Number of subjects: 10
Study 8552741 — intervention group
Group type: COMPARATOR
Intervention: Saline administered to the other forearm
Number of subjects: 10
Study 2190865 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (profound acid suppression)
Number of subjects: 0
Study 2190865 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (control)
Number of subjects: 0
Study 39900 — intervention group
Group type: EXPERIMENTAL
Intervention: Melperone (Buronil)
Number of subjects: 0
Study 39900 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31764003 — intervention group
Group type: EXPERIMENTAL
Intervention: sublingual nifedipine
Number of subjects: 120
Study 31764003 — intervention group
Group type: COMPARATOR
Intervention: control group
Number of subjects: 120
Study 30739254 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab (45/90 mg subcutaneous for psoriasis and PsA; 130 mg or weight-based dosing for CD)
Number of subjects: 6280
Study 28122895 — intervention group
Group type: EXPERIMENTAL
Intervention: 21-gene recurrence score (RS)
Number of subjects: 1065
Study 28122895 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathologic nodal status
Number of subjects: 1065
Study 28122895 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor size
Number of subjects: 1065
Study 28985917 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy inhalation (sweet orange and lavender oil) for one month
Number of subjects: 62
Study 28985917 — intervention group
Group type: COMPARATOR
Intervention: Standard hemodialysis treatment (control group)
Number of subjects: 62
Study 24177257 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 months of dual antiplatelet therapy (aspirin 100-200 mg daily and clopidogrel 75 mg daily)
Number of subjects: 3119
Study 24177257 — intervention group
Group type: COMPARATOR
Intervention: 12 months of dual antiplatelet therapy (aspirin 100-200 mg daily and clopidogrel 75 mg daily)
Number of subjects: 3119
Study 21867445 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg rosuvastatin
Number of subjects: 50
Study 21867445 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 19417125 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (45 mg/day)
Number of subjects: 27
Study 19417125 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 17355726 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief, friendly social connection with an experimenter
Number of subjects: 0
Study 17355726 — intervention group
Group type: COMPARATOR
Intervention: Neutral interaction with an experimenter
Number of subjects: 0
Study 17355726 — intervention group
Group type: COMPARATOR
Intervention: Traditional mood induction
Number of subjects: 0
Study 17355726 — intervention group
Group type: EXPERIMENTAL
Intervention: Writing about a family member, friend, or favourite celebrity
Number of subjects: 0
Study 15067427 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic bolus tracking
Number of subjects: 98
Study 15067427 — intervention group
Group type: COMPARATOR
Intervention: Fixed time-delay examination (30 s delay)
Number of subjects: 98
Study 11287528 — intervention group
Group type: EXPERIMENTAL
Intervention: Ash split catheter
Number of subjects: 94
Study 11287528 — intervention group
Group type: EXPERIMENTAL
Intervention: Opti-flow catheter
Number of subjects: 94
Study 11287528 — intervention group
Group type: EXPERIMENTAL
Intervention: Tesio catheter
Number of subjects: 94
Study 11287528 — intervention group
Group type: COMPARATOR
Intervention: Comparison of all catheters
Number of subjects: 94
Study 9787863 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil combined with desflurane (0.5 MAC = 3.0 vol%)
Number of subjects: 40
Study 9787863 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil combined with propofol (6 mg/kg/h)
Number of subjects: 40
Study 8087442 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-conserving therapy
Number of subjects: 80
Study 8087442 — intervention group
Group type: COMPARATOR
Intervention: Total mastectomy
Number of subjects: 80
Study 8087442 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study 2502799 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous m-chlorophenylpiperazine (0.1 mg/kg)
Number of subjects: 0
Study 2502799 — intervention group
Group type: COMPARATOR
Intervention: Oral m-chlorophenylpiperazine (0.5 mg/kg)
Number of subjects: 0
Study 782699 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyl‐CCNU and 5‐fluorouracil (5‐FU) combination
Number of subjects: 0
Study 782699 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyl‐CCNU
Number of subjects: 0
Study 782699 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyl‐CCNU and cyclophosphamide combination
Number of subjects: 0
Study 782699 — intervention group
Group type: EXPERIMENTAL
Intervention: CCNU
Number of subjects: 0
Study 782699 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptozotocin
Number of subjects: 0
Study 31944791 — intervention group
Group type: EXPERIMENTAL
Intervention: OCPD
Number of subjects: 107
Study 31944791 — intervention group
Group type: COMPARATOR
Intervention: AvPD
Number of subjects: 107
Study 31264766 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel TAAR shampoo
Number of subjects: 24
Study 31264766 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 29054024 — intervention group
Group type: EXPERIMENTAL
Intervention: Social skills plus relaxation training (SSRT)
Number of subjects: 1
Study 26051568 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure at acupoints Neiquan (P6) and Zusanli (ST36) for 3 consecutive days
Number of subjects: 60
Study 26051568 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving regular postoperative care
Number of subjects: 60
Study 23283356 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.4 µg/kg)
Number of subjects: 26
Study 23283356 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1.0 µg/kg)
Number of subjects: 26
Study 23283356 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 21107246 — intervention group
Group type: EXPERIMENTAL
Intervention: FD‐ASOCT (RTVue‐100) for measuring tear meniscus height, depth, and cross-sectional area; corneal fluorescein staining; tear film breakup time; Schirmer I test; dry eye questionnaire.
Number of subjects: 306
Study 21107246 — intervention group
Group type: EXPERIMENTAL
Intervention: FD‐ASOCT (RTVue‐100)
Number of subjects: 306
Study 19211707 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-only (EXO; 12 weeks of exercise without diet-restriction)
Number of subjects: 79
Study 19211707 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric-diet (DIO; 8 weeks of very low energy diet (VLED 600 kcal/day) followed by 4-weeks weight maintenance diet)
Number of subjects: 79
Study 19211707 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric-diet and exercise (DEX; 8 weeks VLED 800 kcal/day + 4-week weight maintenance diet combined with exercise throughout the 12 weeks)
Number of subjects: 79
Study 19211707 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 79
Study 16713525 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice from a general practitioner (GP)
Number of subjects: 3622
Study 16713525 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral to a clinic
Number of subjects: 3622
Study 16713525 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine replacement
Number of subjects: 3622
Study 16713525 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary treatments (acupuncture and hypnotherapy)
Number of subjects: 3622
Study 16713525 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice from family and friends
Number of subjects: 3622
Study 16713525 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 3622
Study 14718699 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 25 mg daily for 12 months
Number of subjects: 692
Study 14718699 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 692
Study 12584861 — intervention group
Group type: EXPERIMENTAL
Intervention: Domestic bambuteral tablet
Number of subjects: 20
Study 12584861 — intervention group
Group type: EXPERIMENTAL
Intervention: Imported bambuteral tablet
Number of subjects: 20
Study 12584861 — intervention group
Group type: EXPERIMENTAL
Intervention: Domestic terbutaline
Number of subjects: 20
Study 12584861 — intervention group
Group type: EXPERIMENTAL
Intervention: Imported terbutaline
Number of subjects: 20
Study 9222948 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril
Number of subjects: 1749
Study 9222948 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1749
Study 7926148 — intervention group
Group type: EXPERIMENTAL
Intervention: FSH alone (urofollitropin) after pituitary desensitization using buserelin acetate nasal spray
Number of subjects: 773
Study 7926148 — intervention group
Group type: EXPERIMENTAL
Intervention: IVF‐ET
Number of subjects: 773
Study 7926148 — intervention group
Group type: EXPERIMENTAL
Intervention: GIFT
Number of subjects: 773
Study 7926148 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative rates for either treatment
Number of subjects: 773
Study 7926148 — intervention group
Group type: EXPERIMENTAL
Intervention: Women > 40 years old
Number of subjects: 773
Study 7926148 — intervention group
Group type: EXPERIMENTAL
Intervention: Sperm disorder cases in women < 40 years old
Number of subjects: 773
Study 7926148 — intervention group
Group type: EXPERIMENTAL
Intervention: Sperm disorder cases in women > 40 years old
Number of subjects: 773
Study 3281308 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1: '00' Dexon subcutaneous and '00' prolene subcuticular sutures
Number of subjects: 50
Study 3281308 — intervention group
Group type: COMPARATOR
Intervention: Group 2: single layer of interrupted '00' nylon sutures
Number of subjects: 50
Study 31175709 — intervention group
Group type: EXPERIMENTAL
Intervention: Odanacatib (300 mg on day 1, then daily multiple doses of 25 mg to day 21)
Number of subjects: 116
Study 31175709 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin (single 400 mg dose on day 4)
Number of subjects: 116
Study 31175709 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116